Cargando…
Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer
Cetuximab is approved for the treatment of metastatic colorectal cancer (mCRC) with RAS wild-type. Nevertheless, the prognosis remains poor and the effectiveness of cetuximab is limited in KRAS mutant mCRC. Recently, emerging evidence has shown that ferroptosis, a newly discovered form of nonapoptot...
Autores principales: | Yang, Jiawen, Mo, Jiajie, Dai, Juji, Ye, Chenqiao, Cen, Wei, Zheng, Xuzhi, Jiang, Lei, Ye, Lechi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590697/ https://www.ncbi.nlm.nih.gov/pubmed/34775496 http://dx.doi.org/10.1038/s41419-021-04367-3 |
Ejemplares similares
-
Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab
por: Liu, Shujie, et al.
Publicado: (2022) -
Low-Concentration PTX And RSL3 Inhibits Tumor Cell Growth Synergistically By Inducing Ferroptosis In Mutant p53 Hypopharyngeal Squamous Carcinoma
por: Ye, Jing, et al.
Publicado: (2019) -
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010) -
PUM1 Is Overexpressed in Colon Cancer Cells With Acquired Resistance to Cetuximab
por: Liu, Qizhi, et al.
Publicado: (2021) -
The RSL3 Induction of KLK Lung Adenocarcinoma Cell Ferroptosis by Inhibition of USP11 Activity and the NRF2-GSH Axis
por: Zhang, Wenlong, et al.
Publicado: (2022)